Epratuzumab

Identification

Name
Epratuzumab
Accession Number
DB04958
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monotclonal antibody, LL2 (EPB-2). Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).

Protein structure
Db04958
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • anti-CD22 IgG
  • humanised anti-CD22 antibody
International/Other Brands
LymphoCide
Categories
UNII
3062P60MH9
CAS number
205923-57-5

Pharmacology

Indication

Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.

Pharmacodynamics
Not Available
Mechanism of action

Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

TargetActionsOrganism
UB-cell receptor CD22Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Epratuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Epratuzumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Epratuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Epratuzumab is combined with Adecatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Epratuzumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Epratuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epratuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Epratuzumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Epratuzumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when Epratuzumab is combined with AMG 108.
Food Interactions
Not Available

References

General References
  1. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24. [PubMed:16864854]
  2. Steinfeld SD, Youinou P: Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther. 2006 Sep;6(9):943-9. [PubMed:16918261]
  3. Goldenberg DM: Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53. [PubMed:17069520]
  4. Dorner T, Goldenberg DM: Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007 Oct;3(5):953-9. [PubMed:18473018]
External Links
PubChem Substance
347909859
Wikipedia
Epratuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentB-Cell NHL / NHL / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2Unknown StatusTreatmentRecurrent or Refractory B Cell Acute Lymphoblastic Leukaemia1
2CompletedTreatmentB ALL / CD22+ Expression / Refractory B-ALL1
2CompletedTreatmentLeukemias1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)4
2TerminatedTreatmentLeukemias / Pediatric Cancer1
2TerminatedTreatmentLupus Erythematosus, Systemic1
2TerminatedTreatmentWaldenström's Macroglobulinemia (WM)1
2Unknown StatusTreatmentMalignant Lymphomas1
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)3
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)2
3Unknown StatusTreatmentMalignant Lymphomas1
3WithdrawnTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedNot AvailableLymphomas: Non-Hodgkin / Lymphomas: Non-Hodgkin Cutaneous Lymphoma / Lymphomas: Non-Hodgkin Diffuse Large B-Cell / Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell / Lymphomas: Non-Hodgkin Mantle Cell / Lymphomas: Non-Hodgkin Marginal Zone / Lymphomas: Non-Hodgkin Peripheral T-Cell / Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Carbohydrate binding
Specific Function
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-link...
Gene Name
CD22
Uniprot ID
P20273
Uniprot Name
B-cell receptor CD22
Molecular Weight
95347.07 Da
References
  1. Steinfeld SD, Youinou P: Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther. 2006 Sep;6(9):943-9. [PubMed:16918261]
  2. Leonard JP, Goldenberg DM: Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene. 2007 May 28;26(25):3704-13. [PubMed:17530024]
  3. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007 Feb;44(6):1331-41. Epub 2006 Jun 30. [PubMed:16814387]

Drug created on October 21, 2007 16:23 / Updated on November 02, 2018 06:07